AngioInsight, Inc. — SEC Form D Filing

AngioInsight, Inc. filed an SEC Form D on November 10, 2026, reporting $16.31M raised in Healthcare AI & Diagnostics.

Form D filing details

Filing
SEC Form D
Filing date
November 10, 2026
Amount reported
$16.31M
Round stage
Seed
Industry
Healthcare AI & Diagnostics
Website
https://www.angioinsight.com/

What the company does

Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Standard angiography relies on subjective visual assessments and often fails to detect abnormalities in small blood vessels, leading to coronary microvascular disease (CMD) being frequently underdiagnosed or misdiagnosed, especially in women.

Solution

AngioInsight is developing the AngioAI+ software platform, which analyzes standard angiographic video to assess stenosis, physiology, and microvascular function. The platform combines Coronary Artery Disease and Coronary Microvascular Disease evaluations into a single automated workflow without requiring additional hardware.

Why now

Growing clinical awareness of ischemia with non-obstructive coronary arteries (INOCA/CMD) coincides with advancements in AI computer vision capable of extracting physiological insights from existing fluoroscopy workflows.

Verdict

This cleared because investors bought a software-only wedge to eliminate expensive, invasive pressure wires in the cath lab, not because they believed microvascular AI would instantly command new standalone reimbursement. Backing a $16.3M seed meant betting that interventionalists will trust computer vision over physical sensor wires to diagnose both macro- and microvascular disease. The upside remains capped by the reality that cath lab software is historically absorbed or commoditized by C-arm imaging incumbents before achieving standalone venture scale.

Source: SEC EDGAR Form D filing